
-
Arrowhead Pharmaceuticals NasdaqGS:ARWR Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Location: 177 East Colorado Boulevard, Suite 700, Pasadena, CA, 91105, United States | Website: https://arrowheadpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.969B
Cash
1.095B
Avg Qtr Burn
N/A
Short % of Float
10.95%
Insider Ownership
13.02%
Institutional Own.
77.24%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Plozasiran (ARO-APOC3) Details Familial chylomicronemia syndrome | PDUFA Approval decision | |
Plozasiran (ARO-APOC3) Details Severe hypertriglyceridemia | Phase 3 Data readout | |
Fazirsiran (ARO-AAT) (TAK-999) Details Severe alpha-1 antitrypsin deficiency, Liver disease | Phase 3 Update | |
Plozasiran (ARO-APOC3) Details Dyslipidemia | Phase 3 Initiation | |
Zodasiran (ARO-ANG3) Details Dyslipidemia | Phase 2b Update | |
ARO-ANG3 Details Dyslipidemia | Phase 2 Update | |
ARO-DM1 Details Myotonic Dystrophy Type 1 | Phase 1/2 Data readout | |
ARO-INHBE Details Obesity, Metabolic disorder | Phase 1/2 Data readout | |
ARO-CFB Details Complement mediated diseases, Kidney disease, IgA nephropathy | Phase 1/2 Data readout | |
ARO-C3 (RNAi) Details Paroxysmal nocturnal hemoglobinuria , Renal disease, IgA nephropathy, C3 Glomerulopathy | Phase 1/2 Data readout | |
ARO-MMP7 Details Idiopathic pulmonary fibrosis | Phase 1/2 Data readout | |
ARO-MUC5AC Details Lung disease, Muco-Obstructive Lung Diseases | Phase 1/2 Data readout | |
ARO-RAGE Details Muco-Obstructive Lung Diseases, Inflammatory disease, Asthma | Phase 1/2 Update | |
ARO-ALK7 Details Obesity | Phase 1/2 Initiation | |
ARO-DUX4 Details Facioscapulohumeral muscular dystrophy | Phase 1/2 Initiation | |
JNJ-3989 (ARO-HBV) Details Hepatitis B | Failed Discontinued | |
ARO-HSD Details Liver disease, Non-alcoholic steatohepatitis | Failed Discontinued |